Alliancebernstein L.P. Iovance Biotherapeutics, Inc. Transaction History

Alliancebernstein L.P.

$290 Billion
Q2 2025

A detailed history of Alliancebernstein L.P. transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 258,890 shares of IOVA stock, worth $471,179. This represents 0.0% of its overall portfolio holdings.

Number of Shares

258,890

Previous 263,490 1.75%

Holding current value

$471,179

Previous $877,000 49.26%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$1.66 - $3.61 $7,636 - $16,606	-4,600 Reduced 1.75%	258,890 $445,000
Q1 2025 May 15, 2025	SELL	$3.33 - $7.79 $1.67 Million - $3.91 Million	-501,909 Reduced 65.57%	263,490 $877,000
Q4 2024 Feb 12, 2025	BUY	$7.17 - $12.28 $962,708 - $1.65 Million	134,269 Added 21.27%	765,399 $5.66 Million
Q3 2024 Nov 14, 2024	BUY	$7.28 - $11.9 $2.19 Million - $3.58 Million	301,098 Added 91.23%	631,130 $5.93 Million
Q2 2024 Aug 14, 2024	BUY	$7.78 - $14.19 $113,525 - $207,060	14,592 Added 4.63%	330,032 $2.65 Million
Q1 2024 May 14, 2024	BUY	$7.59 - $17.47 $474,754 - $1.09 Million	62,550 Added 24.73%	315,440 $4.67 Million
Q4 2023 Feb 14, 2024	SELL	$3.3 - $8.89 $297,990 - $802,767	-90,300 Reduced 26.31%	252,890 $2.06 Million
Q3 2023 Nov 14, 2023	SELL	$4.44 - $8.79 $2.35 Million - $4.65 Million	-528,913 Reduced 60.65%	343,190 $1.56 Million
Q2 2023 Aug 15, 2023	SELL	$5.36 - $9.06 $423,059 - $715,096	-78,929 Reduced 8.3%	872,103 $6.14 Million
Q1 2023 May 15, 2023	BUY	$5.53 - $8.22 $3.41 Million - $5.07 Million	617,131 Added 184.82%	951,032 $5.81 Million
Q4 2022 Feb 14, 2023	BUY	$5.62 - $10.0 $912,693 - $1.62 Million	162,401 Added 94.69%	333,901 $2.13 Million
Q2 2022 Aug 15, 2022	BUY	$6.38 - $18.33 $678,449 - $1.95 Million	106,340 Added 163.2%	171,500 $1.89 Million
Q1 2022 May 13, 2022	SELL	$12.38 - $19.1 $2.33 Million - $3.6 Million	-188,547 Reduced 74.32%	65,160 $1.09 Million
Q4 2021 Feb 14, 2022	BUY	$16.55 - $27.63 $292,355 - $488,083	17,665 Added 7.48%	253,707 $4.84 Million
Q3 2021 Nov 10, 2021	BUY	$20.35 - $26.63 $2.59 Million - $3.39 Million	127,366 Added 117.2%	236,042 $5.82 Million
Q2 2021 Jul 30, 2021	SELL	$16.33 - $33.07 $37 Million - $75 Million	-2,267,138 Reduced 95.43%	108,676 $2.83 Million
Q1 2021 May 06, 2021	BUY	$28.67 - $52.59 $16.9 Million - $31 Million	589,285 Added 32.98%	2,375,814 $75.2 Million
Q4 2020 Feb 08, 2021	BUY	$28.04 - $50.26 $16.1 Million - $28.8 Million	573,719 Added 47.3%	1,786,529 $82.9 Million
Q3 2020 Nov 12, 2020	SELL	$27.75 - $36.3 $4.43 Million - $5.8 Million	-159,819 Reduced 11.64%	1,212,810 $39.9 Million
Q2 2020 Aug 13, 2020	SELL	$27.21 - $41.0 $1.65 Million - $2.49 Million	-60,763 Reduced 4.24%	1,372,629 $37.7 Million
Q1 2020 May 14, 2020	SELL	$19.54 - $38.85 $8.57 Million - $17 Million	-438,444 Reduced 23.42%	1,433,392 $42.9 Million
Q4 2019 Feb 18, 2020	BUY	$17.95 - $29.41 $1.45 Million - $2.37 Million	80,699 Added 4.51%	1,871,836 $51.8 Million
Q3 2019 Nov 14, 2019	BUY	$17.99 - $26.0 $11.8 Million - $17 Million	653,618 Added 57.46%	1,791,137 $32.6 Million
Q2 2019 Aug 14, 2019	BUY	$9.78 - $24.52 $8.92 Million - $22.4 Million	912,419 Added 405.34%	1,137,519 $27.9 Million
Q1 2019 May 14, 2019	BUY	$8.41 - $11.26 $630,750 - $844,500	75,000 Added 49.97%	225,100 $2.14 Million
Q4 2018 Feb 13, 2019	BUY	$7.51 - $11.93 $35,297 - $56,071	4,700 Added 3.23%	150,100 $1.33 Million
Q2 2018 Aug 13, 2018	SELL	$12.45 - $16.95 $880,215 - $1.2 Million	-70,700 Reduced 32.72%	145,400 $1.86 Million
Q1 2018 May 14, 2018	BUY	$8.1 - $19.5 $1.25 Million - $3.01 Million	154,500 Added 250.81%	216,100 $3.65 Million
Q3 2017 Nov 13, 2017	BUY	$4.45 - $8.55 $274,120 - $526,680	61,600	61,600 $477,000

Others Institutions Holding IOVA

# of Institutions

291

Shares Held

232M

Call Options Held

1.14M

Put Options Held

1.15M

View Full List

About IOVANCE BIOTHERAPEUTICS, INC.

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $287M
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

More about IOVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account

Alliancebernstein L.P. Iovance Biotherapeutics, Inc. Transaction History